RALEIGH, N.C., July 27, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (NASDAQ:INCR), a leading global Phase I to Phase IV contract research organization, today reported financial results for the second quarter and year-to-date periods ended June 30, 2017.
“INC delivered a second consecutive quarter of record gross and net awards, building on our momentum from the first quarter,” said Chief Executive Officer Alistair Macdonald. “We continue to see strong demand among small to mid-sized customers and are enhancing our competitive position with larger biopharma, resulting in a robust backlog for the fourth quarter of this year and the full year 2018. This momentum is continuing into the third quarter, with INC delivering two awards from a large Chinese pharma company totaling $84 million, our largest-ever awards in China.” He continued, “Accordingly, we are cautiously optimistic that we are on the path to returning the Company to double-digit organic revenue growth in 2018. We believe our continued strong awards demonstrate our customers’ confidence in our strategy and our ability to execute through the integration with inVentiv Health.”
